Equities analysts forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) will announce sales of $430,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest sales estimate coming in at $850,000.00 and the lowest estimate coming in at $180,000.00. Inovio Pharmaceuticals reported […]
Equities analysts expect that Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) will report sales of $430,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $180,000.00 and the highest estimate coming in at $850,000.00. Inovio Pharmaceuticals reported sales […]
Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a […]
Brokerages forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) will post ($0.28) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Inovio Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.25). Inovio Pharmaceuticals reported […]
Vivos (OTCMKTS:RDGL – Get Rating) and Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership. Risk & Volatility Vivos has a beta of 2.27, meaning […]